Dr Uticaj Adiponektina, plazme D-dimera, upala i marker tumora na kliničke karakteristike i prognozu pacijenata sa karcinomom jajnika
Adiponektin, plazma D-dimer, upala i markeri tumora o kliničkim karakteristikama i prognozi pacijenata sa karcinomom jajnika
Sažetak
[Sažetak] Cilj: Istražiti učinke adiponektina (ADPN), plazma D-dimera (D-D) u plazmi, upala i markera tumora na kliničke karakteristike i prognozu pacijenata sa karcinomom jajnika. Metode: Ukupno 80 bolesnika s karcinomom jajnika liječenih u našoj bolnici od aprila 2017. do novembra 2019. godine bilo je upisano kao ispitanici koji su ravnomjerno podijeljeni u promatračku grupu (pacijenti s karcinomom jajnika) i kontrolnu skupinu (bolesnici s benignim tumorom jajnika) na temelju rezultati postoperativne patološke biopsije. Nivoi ADPN-a, D-D u plazmi, faktori upale i markeri tumora u serumu [ugljikohidratni antigen 125 (CA125), protein epididimisa humane 4 (HE4) i algoritam rizika od zloćudnog jajnika (ROMA)] uspoređeni su između dvije skupine. Istražena je dijagnostička vrijednost markera tumora seruma CA125, HE4 i ROMA kod raka jajnika. Analizirane su korelacije promjena ROMA-e s promjenama nivoa ADPN-a, D-D u plazmi, C-reaktivnog proteina visoke osjetljivosti (hs-CRP), CA125 i HE4. Osim toga, povezani faktori rizika koji utječu na razvoj raka jajnika podvrgnuti su univarijantnim i multivarijantnim logističkim regresijskim analizama. Rezultati: U odnosu na kontrolnu grupu, promatračka grupa pokazala je sniženi nivo ADPN-a (p <0,05), značajno povišene nivoe plazme DD, faktore zapaljenja hs-CRP i interleukin-6 (IL-6) i serumske markere tumora CA125 i HE4 i evidentno povećan ROMA (p <0,05). Pored toga, detekcija ROMA u serumu pokazala je najveću specifičnost i osetljivost i nisku lažnu pozitivnu i lažno negativnu stopu. Promjene ROMA-e bile su pozitivno povezane s promjenama razine D-D, hs-CRP, CA125 i HE4 u plazmi (p <0,05) i negativno su povezane s promjenama razine ADPN-a (p <0,05). Rezultati univarijantne analize pokazali su da su abnormalni nivoi ADPN, D-D, hs-CRP, IL-6, CA125 i HE4 povezani faktori rizika koji utječu na razvoj raka jajnika. Ustanovljeno je pomoću multivarijantne logističke regresijske analize koja je smanjila nivo ADPN-a i povećali nivo D-D, hs-CRP, IL-6, CA125 i HE4 neovisni faktori rizika koji utječu na razvoj raka jajnika. Zaključak: U slučaju raka jajnika, nivo ADPN opada, dok nivoi D-D u plazmi, upalni faktori i markeri tumora u serumu CA125, HE4 i ROMA očito rastu. Pored toga, nivo ROMA pokazuje pozitivan odnos na sadržaj CA125, HE4, D-D plazme i faktore zapaljenja i negativnu povezanost sa nivoom ADPN.
Reference
[2]Choi J, Park CS, Seong MK, Seol H, Kim JS, Park IC, Noh WC, Kim HA.Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status.J Breast Cancer，2019，23(1):10-19.
[3]Ostmeyer J, Lucas E, Christley S, Lea J, Monson N, Tiro J, Cowell LG.Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.PLoS One，2020，15(3):e0229569.
[4]Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S.PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.Mol Cancer，2020，19(1):49.
[5]Kaur K, Rajeshwari M, Gurung N, Kumar H, Sharma MC, Yadav R, Kumar S, Manchanda S, Singhal S, Mathur SR.Uterine tumor resembling ovarian sex cord tumor: A series of six cases displaying varied histopathological patterns and clinical profiles.Indian J Pathol Microbiol，2020，63(Supplement):S81-S86.
[6]Chen Z, Guo X, Sun S, Lu C, Wang L.Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses.Bioengineered，2020，11(1):311-317.
[7]Hurley LC, Levin NK, Chatterjee M, Coles J, Muszkat S, Howarth Z, Dyson G, Tainsky MA.Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.Cancer Biomark，2020，27(3):407-421.
[8]Miao R, Badger TC, Groesch K, Diaz-Sylvester PL, Wilson T, Ghareeb A, Martin JA, Cregger M, Welge M, Bushell C.Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.PLoS One,2020,15(1):e0227707.
[9]Singh MS, Goldsmith M, Thakur K, Chatterjee S, Landesman-Milo D, Levy T, Kunz-Schughart LA, Barenholz Y.An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics.Nanoscale,2020,12(3):1894-1903.
[10]Nomelini RS, Carrijo Chiovato AF, Abdulmassih FBF, da Silva RC, Tavares-Murta BM, Murta EFC.Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies.J Cancer Res Ther,2019,15(6):1226-1230.
[11]Salminen L, Nadeem N, Jain S, Grènman S, Carpén O, Hietanen S, Oksa S, Lamminmäki U, Pettersson K, Gidwani K.A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.Gynecol Oncol,2020,156(3):689-694.
[12]Iwahashi N, Inai Y, Minakata S, Sakurai S, Manabe S, Ito Y, Ino K, Ihara Y.C-Mannosyl tryptophan increases in the plasma of patients with ovarian cancer.Oncol Lett,2020,19(1):908-916.
[13]Maděrka M, Pilka R, Neubert D, Hambálek J.New serum tumor markers S100, TFF3 and AIF-1 and their possible use in oncogynecology.Ceska Gynekol,2019,84(4):303-308.
[14]Turashvili G, Fix DJ, Soslow RA, Park KJ.Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases.Int J Gynecol Pathol,2020,39(1):72-78.
[15]Chin CD, Fares CM, Konecny GE, Rao J.Biomarkers that may predict response to immunotherapy in ovarian malignancies.Curr Opin Obstet Gynecol,2020,32(1):84-90.
[16]Wolf D, Fiegl H, Zeimet AG, Wieser V, Marth C, Sprung S, Sopper S, Hartmann G, Reimer D, Boesch M.High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.Int J Cancer,2020,146(7):2007-2018.
[17]Sullivan MW, Modesitt SC.When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors.South Med J,2019,112(12):634-638.
[18]Li H, Terry MB, Antoniou AC, Phillips KA, Kast K, Mooij TM, Engel C, Noguès C, Stoppa-Lyonnet D, Lasset C.Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium.Cancer Epidemiol Biomarkers Prev,2020,29(2):368-378.
[19]Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).J Immunother Cancer,2019,7(1):332-336.
[20]Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.Cancer Immunol Immunother,2020,69(1):33-42.
Sva prava zadržana (c) 2021 Hui Li
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.